ArticleBleeding, thrombosis and vascular biology2026
Trypsin is as procoagulant as factor XIIa.
Article in Bleeding, thrombosis and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Background: To help shed light on the roles of the contact pathway of blood clotting, we quantified the relative procoagulant activities of each of the serine proteases of the clotting cascade. Methods: We added varying concentrations of the activated forms of different clotting proteases to normal human plasma and recorded the time to clot formation. We also compared these clotting activities to that of the nonspecific serine protease, trypsin. Results: The activated proteases of the final common pathway of blood clotting exhibited relatively strong clotting activity and achieved 100-second clotting times at pM to very low nM concentrations. In contrast, factor XIIa and plasma kallikrein exhibited weak clotting activity such that it required nearly 100 nM factor XIIa to achieve a 100-second clotting time, and for plasma kallikrein this was not achieved even with 100 nM enzyme. Trypsin was slightly more procoagulant than factor XIIa. Conclusions: The enzymes that trigger the contact pathway of blood clotting have remarkably weak procoagulant activity. The implications for the roles of factor XII and trypsin in thrombotic disorders and pancreatitis are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.